-
Mashup Score: 7Wafik S. El-Deiry: The published version of our paper that’s out as a preprint - OncoDaily - 1 day(s) ago
Wafik S. El-Deiry: The published version of our paper that’s out as a preprint / Brown University, cancer, COVID vaccines, David Gorski, Legorreta Cancer
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer - 1 day(s) ago
Nature Communications – CDK4/6 inhibitors have improved outcomes for patients with ER+ breast cancer, however, those with loss of RB1 function often fail to respond. Here, the authors identify a…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Single-Cell Untargeted Lipidomics Using Liquid Chromatography and Data-Dependent Acquisition after Live Cell Selection - 1 day(s) ago
We report the development and validation of an untargeted single-cell lipidomics method based on microflow chromatography coupled to a data-dependent mass spectrometry method for fragmentation-based identification of lipids. Given the absence of single-cell lipid standards, we show how the methodology should be optimized and validated using a dilute cell extract. The methodology is applied to dilute pancreatic cancer and macrophage cell extracts and standards to demonstrate the sensitivity requirements for confident assignment of lipids and classification of the cell type at the single-cell level. The method is then coupled to a system that can provide automated sampling of live, single cells into capillaries under microscope observation. This workflow retains the spatial information and morphology of cells during sampling and highlights the heterogeneity in lipid profiles observed at the single-cell level. The workflow is applied to show changes in single-cell lipid profiles as a resp
Source: pubs.acs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Michael Shusterman: Just a reminder about why we should NOT use bolus 5-FU in combination with the infusion - OncoDaily - 2 day(s) ago
Michael Shusterman: Just a reminder about why we should NOT use bolus 5-FU in combination with the infusion / 5-Fluouracil, ASCO, cancer, chemotherapy,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Unraveling cellular complexity with transient adapters in highly multiplexed super-resolution imaging - 3 day(s) ago
Development of FLASH-PAINT enables rapid and efficient visualization of cellular organelles, using a potentially unlimited number of labels.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Nature Methods – SpatialData is a user-friendly computational framework for exploring, analyzing, annotating, aligning and storing spatial omics data that can seamlessly handle large multimodal…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1226SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells - 5 day(s) ago
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 infection has led to worsened outcomes for patients with cancer. SARS-CoV-2 spike protein mediates host cell infection and cell-cell fusion that causes stabilization of tumor suppressor p53 protein. In-silico analysis previously suggested that SARS-CoV-2 spike interacts with p53 directly but this putative interaction has not been demonstrated in cells. We examined the interaction between SARS-CoV-2 spike, p53 and MDM2 (E3 ligase, which mediates p53 degradation) in cancer cells using an immunoprecipitation assay. We observed that SARS-CoV-2 spike protein interrupts p53-MDM2 protein interaction but did not detect SARS-CoV-2 spike bound with p53 protein in the cancer cells. We further observed that SARS-CoV-2 spike suppresses p53 transcriptional activity in cancer cells including after nutlin exposure of wild-type p53-, spike S2-expressing tumor cells and inhibits chemotherapy-induced p53 gene activation of p21(WAF1
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Parking spots are selling for as much as $500,000 in Boston. Realtors aren’t surprised. - The Boston Globe - 5 day(s) ago
Parking spot sales are rare, and difficult to track. But when the true cost is revealed, they can provide a stark indication of how expensive the Boston housing market is.
Source: www.bostonglobe.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Every New Memory You Make Causes Damage to Your Brain Cells - 5 day(s) ago
Try to forget about it.
Source: apple.newsCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
Cancer therapy is often limited by toxicity from pneumonitis. This often-lethal side effect is known to be impacted by innate immunity, and in particular the pathways regulated by the TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from the lethal effects of radiation. We found that two different agonists, parenteral PEGylated trimeric-TRAIL (TLY012) and oral TRAIL-Inducing Compound #10 (TIC10/ONC201), could achieve this goal. Both compounds could completely protect mice from lethality by reducing pneumonitis, alveolar-wall thickness, and oxygen desaturation. At the molecular level, this protection appeared to be due to the inhibition of CCl22, a macrophage-derived chemokine previously associated with radiation pneumonitis and pulmonary fibrosis. The discovery that short-term treatment with TRAIL pathway agonists effectively rescues animals from high doses of radiation exposure has important translational implications. One Sentence Summary Prevention of
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet-
We have a strategy to mitigate radiation-induced lung injury and dermatitis but it remains as unfunded research thanks to @NIH/@theNCI peer reviewers. Here’s our preprint from June, 2023 https://t.co/mRhEmRx98Y Our manuscript continues to be under revision for publication which… https://t.co/pYHJnbbDEr
-
RT @oncodaily: The published version of our paper that’s out as a preprint - @weldeiry https://t.co/IUEcfesthf @biorxivpreprint Shenglian…